Biotech Bullish Stocks: TrovaGene Inc (NASDAQ:TROV), Sorrento Therapeutics (NASDAQ:SRNE), Marina Biotech (OTCMKTS:MRNA), Cara Therapeutics (NASDAQ:CARA)
Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, reported its financial results for the quarter and the year ended December 31, 2013 .In 2013, we transitioned from a technology-driven company to one focused on building a body of clinical evidence, including health economic data, to demonstrate how our molecular diagnostic platform may change the way cancer patients are treated,” stated Antonius Schuh, Ph.D., chief executive officer of Trovagene. “This year, we plan to release additional oncogene mutation assays to broaden the reach of our technology, and to present additional clinical study results to establish the value of our innovative platform. TrovaGene Inc (NASDAQ:TROV) shares after opening at $5.95 moved to $6.51 on last trade day and at the end of the day closed at $6.20. Company price to sales ratio in past twelve months was calculated as 277.00 and price to cash ratio as 3.99. TrovaGene Inc (NASDAQ:TROV) showed a positive weekly performance of 5.80%.
Sorrento Therapeutics Inc. (Nasdaq: SRNE) a San Diego late-stage clinical oncology company developing new treatments for cancer and associated pain, has added Mark W. Durand to its board of directors. Sorrento Therapeutics Inc (NASDAQ:SRNE) shares advanced 5.60% in last trading session and ended the day on $13.96. SRNE return on equity ratio is recorded as -112.80% and its return on assets is -92.60%. Sorrento Therapeutics Inc (NASDAQ:SRNE) yearly performance is 179.20%.
Marina Biotech, Inc. (OTCMKTS:MRNA) which is a small capped drug maker HQ’ed in Bothell has been in the news last week for two reasons. One is the update it provided on its roadmap for developing new drugs using its proprietary compounds, and the second is the raising of $6 million in proceeds through the sale of some of its shares. The two updates had been made by the firm on 11th March, and had led to intense investor interest in the stock. This resulted in a 15 percent increase in market valuation during trading in the past week. Marina Biotech, Inc. (OTCMKTS:MRNA) shares moved up 7.69% in last trading session and was closed at $1.54, while trading in range of $1.45-$1.61. Marina Biotech, Inc. (OTCMKTS:MRNA) year to date performance is 285.00%.
Stock analysts at Needham & Company LLC initiated coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report issued on Thursday, AnalystRatings.Net reports. The firm set a “buy” rating on the stock. Cara Therapeutics Inc (NASDAQ:CARA) weekly performance is -8.28%. On last trading day company shares ended up $18.50. Cara Therapeutics Inc (NASDAQ:CARA) distance from 50-day simple moving average is -2.23%. Analysts mean target price for the company is $23.20.